



Nullity of GSTT1/GSTM1 related to pesticides 
is associated with Parkinson’s disease
Nulidade de GSTT1/GSTM1 relacionada à pesticidas associa-se com doença de Parkinson
Marcela Augusta de Souza Pinhel1, Caroline Leiko Sado2, Gabriela dos Santos Longo3, Michele Lima Gregório1, 
Gisele Sousa Amorim1, Greiciane Maria da Silva Florim1, Camila Montoro Mazeti1, Denise Poltronieri Martins1,  
Fábio de Nazaré Oliveira3, Marcelo Arruda Nakazone4, Waldir Antonio Tognola5, Dorotéia Rossi Silva Souza5
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder, clinically characterized by bradykinesia, rigid-
ity, resting tremor, and postural instability. Early symptoms 
of PD are primarily due to the selective degeneration of do-
paminergic neurons of the substantia nigra, innervating the 
neostriatum. The primary cause of PD is unknown, however, 
mitochondrial failure, oxidative stress and genetic factors, re-
sponsible for neurodegeneration in the substantia nigra are 
investigated hypotheses for the etiology of idiopathic PD1.
The progression of cell loss is thought to occur over a 
somewhat protracted period of time in a defined spatiotem-
poral manner, and the onset of PD symptoms is typically 
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ABSTRACT
Genetic and environmental factors affect the pathogenesis of Parkinson’s disease (PD). Genetic variants of the enzyme glutathione S-trans-
ferases (GST) may be related to the disease. This study aimed to evaluate the influence of genetic variants of GST (GSTT1/GSTM1) and their 
association with the exposure to environmental toxins in PD patients. We studied 254 patients with PD and 169 controls. The GSTM1/GSTT1 
variants were analyzed by polymerase chain reaction. We applied the Fisher’s exact test and the χ2 test for statistical analysis (p<0.05). 
The present and absence for GSTT1 and GSTM1 were similar in patients and controls. The null for GSTT1 and GSTM1 (0/0) and exposure to 
pesticides prevailed in patients (18%) compared to controls (13%, p=0.014). This study suggests the association between PD and previous 
exposure to pesticides, whose effect may be enhanced in combination with null for GSTT1/GSTM1.
Key words: Parkinson disease, glutathione transferase, polymorphism genetic, xenobiotics.
RESUMO
Fatores genéticos e ambientais influenciam a patogênese da doença de Parkinson (DP). Variantes genéticas das enzimas glutationa S-trans-
ferases (GST) parecem estar envolvidas com a doença. Os objetivos deste estudo foram avaliar a influência de variantes genéticas de GST 
(GSTT1/GSTM1) e sua associação com exposição a toxinas ambientais em pacientes com DP. Foram estudados 254 pacientes com DP e 169 
controles. As variantes para GSTM1/GSTT1 foram analisadas por reação em cadeia da polimerase. Para análise estatística foram aplicados 
os testes de Fisher e do χ2 (p<0,05). Tanto a presença quanto a nulidade para GSTT1 e GSTM1 foram semelhantes em pacientes e controles. 
A nulidade para GSTT1 e GSTM1 (0/0) e contato com agrotóxicos prevaleceu nos pacientes (18%) em relação aos controles (13%, p=0,014). 
Este estudo sugere associação entre DP e contato prévio com agrotóxicos, cujo efeito parece potencializado em combinação com nulidade 
para GSTT1/GSTM1.
Palavras-Chave: doença de Parkinson, glutationa transferase, polimorfismo genético, xenobióticos.
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insidious. Biological models suggest that the progression of 
PD includes a long pre symptomatic period, thus there is sig-
nificant potential for interventions that could slow or even 
arrest PD at this stage of the disease. However, there is cur-
rently no appropriate diagnostic test or biomarker that can 
identify this pre symptomatic population2.
Currently, 6.3 million individuals, which represent 1% of 
the world population older than 65 years, are diagnosed with 
PD, and by 2030 this number may increase to 9.3 million3,4. In 
Brazil, statistics show PD’s prevalence of 150/200 for every 
100.000 individuals and annual incidence of 20/100,000 cases5.
Central nervous system is particularly vulnerable to oxi-
dative stress, due to factors such as high levels of oxygen, low 
concentration of antioxidants and their related enzymes. 
It demands a high level of energy and there are polyunsatu-
rated lipids that tend to undergo oxidation. Moreover, iron 
particles may accumulate with advancing age and become 
a strong catalyzer in the formation of oxidative species, in-
cluding free radicals6. Consequently, genetic predisposition 
combined with environmental risk factors may be the cause 
of the nigrostriatal cells degeneration7. Accumulation of such 
reactive substances in dopaminergic neurons may cause 
pathophysiological changes in the brain of PD patients, in-
creased formation of reactive oxygen species and decrease of 
the antioxidant capacity of the tissue8.
It has been suggested that polymorphism in enzymes in-
volved in oxidative metabolism and detoxification could be in-
volved in predisposition to PD. Studies have hypothesized that 
individuals with poor metabolizing status, based on cytochrome 
P4502D6 (CYP2D6) genotype could be at risk to PD9, though in-
consistencies have been reported in the literature10. Similarly, 
polymorphism in enzymes, which generate free radicals or those 
involved in dopamine neurotransmission such as cytochrome 
P450 2E1 (CYP2E1), glutathione S-transferases (GST), superox-
ide dismutase (MnSOD), monoamine oxidase-B (MAO-B), do-
pamine receptor D2 (DRD2) and dopamine transporter (DAT) 
which are known to interact with environmental exposures, 
could be implicated in the pathogenesis of PD1,11.
GST may modify PD risk, since PD is more common 
among people who report the use of pesticides12 and smok-
ers generally have a lower risk of developing PD13. As many 
products of oxidative stress and neurotoxins are detoxified 
by GST enzymes, decreased (impaired) detoxification capaci-
ty may result in an increased PD risk. The phenotypic absence 
of GSTM1 and GSTT1 activity is due to homozygous deletion of 
these genes11.
Oxidative stress activates GST (and its variants M1, T1 
and P1) in order to detoxify many products of lipid, nucle-
ic acid and protein oxidation. GSTM1 and GSTT1 cata-
lyze detoxification of reactive oxygen and products of lipid 
peroxidation14. 
Epidemiologic studies show that null genotypes for 
GSTM1 and GSTT1 are related to the increase of susceptibility 
to oxidative stress associated diseases15. Null genotype for 
GSTM1 (homozygote to the null allele) increases the risk for 
cancer in some tissues and it is also associated with PD16.
Evaluating studies have shown the impact of combined 
genetic polymorphisms and environmental factors in neu-
rodegenerative diseases. Thorough studies should be con-
ducted in various groups of population, in order to charac-
terize smaller specific groups of PD susceptible individuals 
( for example, older patients whose survival time allows a 
cumulative effect of oxidative damage with genotoxic risk). 
This study aimed to analyze the frequency of GST genetic 
variations, including GSTT1 and GSTM1 in patients suffer-
ing from PD and to evaluate the association between GSTT1 
and GSTM1 genotypes and their relation to the exposition to 
environmental toxins in those patients.
METHODS
A group of 423 individuals were selected and distributed 
in two groups: Study Group (SG) — 254 PD patients — and 
Control Group (CG) — 169 individuals with negative diagno-
sis for PD (controls). Mixed ethnicity was considered when 
those groups were created17, independently of gender, fa-
milial history PD or sporadic PD. Patients were selected at 
the Movement Disorders Clinic of the Hospital de Base of 
Faculdade de Medicina de São José do Rio Preto (FAMERP). 
Diagnosis of PD followed the criteria recommended by 
Jankovic18, including bradykinesia, rigidity, tremor at rest, 
postural instability, unilateral onset, response to L-dopa for 
more than five years, levodopa-induced dyskinesia, progres-
sive disorder, persistent asymmetry and clinical course of ten 
years or more, as well as complementary tests18. Controls 
were age matched with patients and were convened in the 
same institution. All subjects were informed about the nature 
of the study and confirmed their willingness to participate 
by signing written consent forms. The study was approved by 
the Ethics Research Committee of FAMERP (Protocol 
nº 151/2008, Certificate of Appreciation Presentation Ethics 
CAAE nº 0029.0.140.000-08).
This was an experimental case-control study. 
Participants were submitted to an interview and invited to 
answer a questionnaire concerning personal data, lifestyle, 
previous pesticide exposure and age at the time of the first 
PD symptoms and other diseases. Peripheral blood was col-
lected in order to obtain analysis of genetic polymorphisms 
for GSTT1 and GSTM1.
Genetic analysis for GSTT1 and GSTM1
The study of polymorphisms was performed in the Center 
for Research in Biochemistry and Molecular Biology of FAMERP 
and consisted of genomic DNA extraction from whole blood sam-
ples19 and DNA amplification by conventional polymerase chain 
529Marcela Augusta de Souza Pinhel et al. Parkinson: enzyme glutathione S-transferase
reaction (PCR). Customs assays were used to determine deletions 
in GSTM1 and GSTT1. Subjects were scored as either having one 
or two copies of the gene (non-null genotype), or as having two 
missing copies of the gene (null genotype). Genetic determina-
tions were made blinded to PD status. 
Each reaction was performed in Eppendorf Mastercycler 
Thermocycler, each tube contained 0.5 mL of nucleotides 
(0.8 mM), 2.5 mL of buffer PCR 10X, 2.5 mL of dimethyl sulfox-
ide 10%, 2.5 mL of each primer (2.5 mM), 0.2 mL of Taq polim-
erase (5 U/mL), 11 mL of Milli Q water, and 2 mL of diluted ge-
nomic DNA (0.2 mg). Primers used: GSTT1 sense: 5’ AAC TCC 
CTA AAA GCT AAA C 3’; GSTT1 non-sense: 5’ GTT GGG CTC 
AAA TAT ACG GTG G 3’; GSTM1 sense: 5’ TTC CTT ACT GGT 
CCT CAC ATC TC 3’; GSTM1 non-sense: 5’ TCA CCG ATC ATG 
GCC AGC A 3’. In the same reaction, CYP1A1 gene was used 
as control, presenting the following primers sequence, sense: 
5’GAA CTG CCA CTT CAG CTG TCT 3’; non-sense: 5’ CAG 
CTG CAT TTG GAA GTG CTC 3’. Initial DNA denaturation 
will be obtained at 94°C during 4 minutes and the reaction mix 
submitted to 39 cycles of 94°C during 2 minutes and 59°C dur-
ing 1 minute, extension at 72 °C during 1 minute and ending 
cycle at 72°C during 10 minutes20.
GSTM1 and GSTT1 did not need enzymatic restric-
tion, and were identified by the presence or the absence of 
the genes (null genotype). Post-PCR product was separated 
by 1.5% agarose gel electrophoresis, under constant elec-
tric current of 150 V during 45 minutes, separating 423 base 
pairs fragments (GSTT1), 310 base pairs (CYP control) and 
230 base pairs (GSTM1). A standard DNA sample (100 base 
pairs  –  Invitrogen) was used as comparison to the electro-
phoretic bands. After the electrophoresis, the gel was stained 
by GelRed® (Uniscience) during 10 minutes and DNA frag-
ments were visualized under ultraviolet light (UV) (Fig 1).
STATISTICAL ANALYSIS
The categorical variables including the allele and geno-
type frequencies for the GSTT1 and GSTM1 genotypes were 
analyzed applying the Fisher’s exact test and the χ2 test. 
Statistical analysis also included Hardy-Weinberg equilib-
rium, t-test and multivariate regression analysis; p<0.05 was 
considered statistically significant. Hardy-Weinberg equilib-
rium was assessed in cases and controls using the χ2 test. 
Departure from Hardy-Weinberg equilibrium may be indica-
tive of genotyping error or non-random selection of controls 
in terms of the distribution of a given polymorphism.
RESULTS
The SG (PD patients) was generally younger (69.2±11.1 
years old) than the CG (71.7±8.0 years old; p=0.008). Male 
gender prevailed in SG in comparison to CG (48%, p=0.006). 
Fig 2 shows the analysis of smoking, drinking and pesti-
cide exposure data. SG had higher smokers prevalence 
(43%) than CG (36%) — however not statistically relevant 
(p=0.225). Frequent alcohol consumption was also higher in 
SG (37%), but it did not differ to CG (34%; P=0.666). On the 
other hand, SG had a higher exposure to pesticides (48%) 
than CG (32%; 0.014).
Table 1 shows absence or presence of GSTM1 and GSTT1 
in PD patients and controls. A similarity was found for both 
presence and absence of GSTT1 among patients (83 and 
17%, respectively) and controls (80 and 20%; p=0.605). For 
GSTM1 genotype, with 54% of frequency and 46% of absence 
in SG, versus 48 and 52% in controls (p=0.319). GSTT1 distri-
bution showed the standard predicted by Hardy-Weinberg 
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Fig 1. Diagram showing electrophoretic profile on agarose 
gel (1.5%) to GSTT1 and GSTM1 genes, presenting the 
corresponding genotypes (presence or absence) to DNA 




















Fig 2. Distribution for smoking and drink habits, and previous 
contact with agrotoxic in patients with Parkinson disease 
and controls. 
M: molecular marker (100 bp).
 *χ2 test; SG: study group; CG: control group.
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the same occurred with GSTM1 (SG – χ2=33.0; p<0.05 and 
CG – χ2=12.0; p<0.05).
Tables 2 to 4 show the distribution of groups accord-
ing to the genetic variations and to environmental factors. 
Similarity in both groups occurred concerning smoking 
(Table 2) and drinking habits (Table 3). It was also observed 
a higher frequency of nullity for GSTT1 and GSTM1 (0/0) 
and contact to pesticides (18%) in patients than CG (13%, 
p=0.014; Table 4). Furthermore, SG showed higher frequency 
for nullity of genotypes (0/0) combined with pesticides than 
GSTM1 (18 versus 6%; p=0.010). On the other hand, patients 
had lower frequency of the combination genotype nullity and 
absence of pesticides (4.2%) compared to presence of GSTT1 
(45%, p=0.0001; Table 4). The same occurred in relation to the 
presence of both genotypes in patients with previous contact 
to pesticides (GSTM1/GSTT1=48%), compared to nullity of 
genotypes (4.2%; p=0.016) in patients without previous expo-
sure to pesticides.
DISCUSSION
In this study, null genotypes for GSTM1 and GSTT1 
showed similarity between SG (17 and 46%, respective-
ly) and CG (20 and 52%, respectively). Nullity for GSTM1 
and GSTT1 in both groups was near to the frequencies 
observed in a study with Pakistani population, which 
showed 42.1 and 25.4%, respectively21. The homozygous 
deletion of these genes, which makes individuals more 
prone to environmental carcinogenic compounds, shows 
prevalence in GSTM1 within the world’s population ( fre-
quency between 45 and 60%), mainly in Caucasians, 
Asians, Spanish and Pakistanis21, while nullity for GSTT1 
is much lower (between 20 and 23%).
Brazilians form one of the most heterogeneous popu-
lations in the world, which is the result of five centuries 
of interethnic crosses of people from three continents: 
the European colonizers, mainly represented by the 
Portuguese, the African slaves, and the autochthonous 
Amerindians. Considering this fact, a specific dissection 
Table 1. Allelic and genotypic frequency for glutathione 





n % n %
GSTT1
+/+ 200 83 133 80
0.6050/0 42 17 33 20
Total 242 100 166 100
GSTM1
+/+ 130 54 80 48
0.3190/0 112 46 86 52
Total 242 100 166 100
SG: study group; CG: control group; *χ2 test;  +/+: presence; 0/0: absence
Table 2. Distribution for patients with Parkinson disease in relation to glutathione S-transferases M1 and T1 genotypes, 









n % n % n % n %
T1/0 33 34.0 52 40.0 17 33.0 40 44.0 0.356
M1/0 10 11.0 7 5.0 4 8.0 7 8.0 0.440
T1M1 42 43.0 63 47.0 22 43.0 35 39.0 0.995
0/0 12 12.0 11 8.0 8 16.0 8 9.0 1.000
Total 97 100.0 133 100.0 51 100.0 90 100.0 –
0/0: nullity for GSTT1 and GSTM1; *Fisher’s or χ2 tests; Patient intragroup analysis: T1 versus M1=0.209; T1 versus T1M1=0.987; T1 versus 0/0=0.360; M1 versus T1M1=0.233; 
M1 versus 0/0=0.923; T1M1 versus 0/0=0.402. Control intragroup analysis: T1 versus M1=0.727; T1 versus T1M1=0.429; T1 versus 0/0=0.228; M1 versus T1M1=1.000; 
M1 versus 0/0=0.696; T1M1 versus 0/0=0.594. Intergroup analysis: T1 versus M1=1.000; T1 versus T1M1=0.966; T1 versus 0/0=0.843; M1 versus T1M1=0.763; M1 versus 
0/0=0.717; T1M1 versus 0/0=0.848.
Table 3. Distribution for patients with Parkinson disease in relation to glutathione S-transferases M1 and T1 polymorphisms, 









n % n % n % n %
T1/0 28 33.6 57 38.5 13 29 43 45 0.291
M1/0 4 5.0 13 9.0 4 9 7 7 0.671
T1M1 38 46.0 67 45.5 23 51 34 36 0.724
0/0 13 15.4 10 7.0 5 11 11 12 0.192
Total 83 100 147 100.0 45 100 95 100 –
0/0: nullity for GSTT1 and GSTM1; *Fisher’s or χ2 tests; Patient intragroup analysis: T1 versus M1=0.572; T1 versus T1M1=0.753; T1 versus 0/0=0.068; M1 versus 
T1M1=0.413; M1 versus 0/0=0.054; T1M1 versus 0/0=0.116. Control intragroup analysis:  T1 versus M1=0.450; T1 versus T1M1=0.079; T1 versus 0/0=0.743; 
M1 versus T1M1=1.000; M1 versus 0/0=1.000; T1M1 versus 0/0=0.710. Intergroup analysis: T1 versus M1=0.423; T1 versus T1M1=0.681; T1 versus 0/0=1.000; 
M1 versus T1M1=0.702; M1 versus 0/0=0.382; T1M1 versus 0/0=0.577.
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Table 4. Distribution for patients with Parkinson disease in relation to glutathione S-transferases M1 and T1 polymorphisms, 









n % n % n % n %
T1/0 32 28.0 53 45.0 10 43.0 20 42.0 0.840
M1/0 7 6.0 10 8.5 2 9.0 5 11.0 0.668
T1M1 55 48.0 50 42.3 8 35.0 16 34.0 0.144
0/0 21 18.0 5 4.2 3 13.0 6 13.0 0.014
Total 115 100.0 118 100.0 23 100.0 47 100.0 –
0/0: nullity for GSTT1 and GSTM1; *Fisher’s test or χ2 tests; Patient intragroup analysis: T1 versus M1=0.784; T1 versus T1M1=0.060; T1 versus 0/0=0.0001; M1 
versus T1M1=0.551; M1 versus 0/0=0.010; T1M1 versus 0/0=0.016. Control intragroup analysis: T1 versus M1=1.000; T1 versus T1M1=1.000; T1 versus 0/0=1.000; 
M1 versus T1M1=1.000; M1 versus 0/0=1.000; T1M1 versus 0/0=1.000. Intergroup analysis: T1 versus M1=1.000; T1 versus T1M1=0.224; T1 versus 0/0=0.345; M1 
versus T1M1=0.602; M1 versus 0/0=0.597; T1M1 versus 0/0=1.000.
of the genetic contribution from each group represents 
serious theoretical difficulties22. In this study, individuals 
with such mixed ethnic background were selected, and 
both patients and controls showed a similar distribution 
of the nullity of GSTM1 and GSTT1. GSTT1 represents a 
protective factor for the individuals, because it is widely 
distributed in genotypes +/+ in both groups (83 and 80% 
respectively). Absence of GSTM1 and of GSTT1 may also 
act on development of PD, because there is no opposition 
to cellular oxidation. However, this condition is rare in 
the general population21. 
Distribution of both genotypes (non-null and null) 
for GSTT1 and GSTM1 did not differ in this study when 
comparing a risk group (smokers and drinkers) to the un-
exposed group. In agreement with previous literature, 
including a meta-analysis by Tan et al.23 and Kiyohara 
et  al.11. An early study of 100 PD cases and 200 controls 
reported that the protective effect of cigarette smok-
ing was lost for patients with the GSTM1 deletion24. The 
GSTM1 null genotype expresses no enzyme activity; one 
could speculate that the loss of enzyme activity may en-
hance the protective effect conferred by a metabolite of 
cigarette smoke that is not metabolized due to lack of this 
enzyme. Accordingly, Wahner et al.25 noted a larger effect 
estimate for smokers with the homozygous deletion com-
pared to smokers without the deletion, yet the confidence 
intervals largely overlapped due to the small sample sizes 
of the subgroups and the interaction analyses indicated 
no departure from multiplicativity.
On the other hand, greater exposition to pesticides 
in SG than CG was observed, with highlight to the com-
bination of nullity for GSTT1/GSTM1 and exposition to 
pesticides in SG. Some studies reveal that certain pes-
ticides (like rotenone) may induce PC-specific symp-
toms26,27. Structurally and functionally, some types of 
pesticides act like inhibitors of mitochondrial complex 
I. In those cases, evidences show that dopaminergic neu-
rons are vulnerable to mitochondrial disfunction28. Toxin 
is captured by dopamine transporters and noradrena-
lin remains stored inside the cell. As a consequence, the 
death of the cell is caused by the formation of reactive 
oxygen species and deficit in the mitochondrial respira-
tory chain11,28. 
Exposition to environmental factors potentiates risk 
for PD, especially considering genetic factors. Studies 
show ethylene oxide or n-hexane associated to a higher 
risk for neurotoxic effects, which suggests the relation 
with GST polymorphisms11. GST detoxified agents are, for 
example, polycyclic aromatic hydrocarbons, which may 
be found in pesticides11. Therefore, individuals with null 
genotype for GSTM1 and GSTT1 have a higher risk for 
oxidative stress associated diseases12,29, including PD10,16. 
However, there is little research on this matter, and even 
less on Brazilian individuals.
The possibility of selection bias is of concern in case-
control studies. Although self-selection is unlikely to be 
related to genotype, selection factors related to environ-
mental risk factors could bias estimates of main gene 
polymorphism effects. However, the gene-environment 
interaction estimates should not be influenced under the 
assumption that genotype does not influence participa-
tion conditional on exposure and disease, even if selec-
tion is jointly influenced by exposures and disease and 
whether or not the genotype is related to exposure, dis-
ease, or both25,30.
This study suggests the association between PD and 
previous pesticide exposure, the effects of which seem to 
be enhanced when combined with the nullity for GSTT1/
GSTM1. This demonstrates the relation between those 
genetic polymorphisms involved in the metabolism of xe-
nobiotics and the environmental factors in PD. Alteration 
of biochemical markers related to oxidative stress in PD 
suggests its participation in this process, turning into a 
consequence or a cause of the disease.
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